If You Invested $1,000 in Aquestive Therapeutics (AQST)
This article analyzes the historical performance of an imagined $1,000 investment in Aquestive Therapeutics (AQST) over one, five, and ten-year periods, showing the total returns and compound annual growth rates. It details Aquestive Therapeutics' business model, proprietary technologies like PharmFilm® and AdrenaVerse™, key pipeline products such as Anaphylm™ and Libervant®, and its financial and regulatory context. The company, which trades on the Nasdaq Global Market under AQST, focuses on developing orally administered pharmaceutical products and alternatives to traditional therapies.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (AQST) for potential corporate wrongdoing. The firm encourages Aquestive stockholders who purchased securities before June 16, 2025, and still hold them, to contact them for more information and to assist in the investigation. The firm operates on a contingency fee basis and aims to recover investor capital and ensure corporate accountability.
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The investigation aims to restore investor capital and ensure corporate accountability, with the firm operating on a contingency fee basis.
SEC Form S-3 filed by Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc. (AQST) filed an S-3 form with the SEC, which was promptly reported by Quantisnow. Quantisnow is a real-time market data and news platform that provides alerts on SEC filings, FDA approvals, analyst ratings, and insider trades to retail investors. The article also mentions recent insider transactions for Aquestive Therapeutics, including share sales by Director Krop Julie and President and CEO Barber Daniel.
Form S-3 Aquestive Therapeutics Inc For: 26 June By Investing.com
This article reports on the filing of Form S-3 by Aquestive Therapeutics Inc. on June 26. The brief notice indicates a regulatory filing related to the company, suggesting potential corporate actions such as a stock offering.
AQST Stock Price and Chart — NASDAQ:AQST
This page provides a comprehensive overview of Aquestive Therapeutics, Inc. (AQST) stock, including its current price, performance across various timeframes, key financial statistics, and upcoming earnings dates. It also features a collection of trading ideas and analyses from the TradingView community, detailing potential movements and technical setups for AQST. The company's profile, sector, and product pipeline are also outlined.
Aquestive Therapeutics, Inc. Actuals & Estimates (NASDAQ:AQST)
This article provides an overview of Aquestive Therapeutics, Inc. (NASDAQ: AQST) stock, including its current price, market capitalization, analyst forecasts, and historical performance. It also details recent financial actuals such as earnings per share and revenue, and forthcoming events like the next earnings report scheduled for August 4, 2026.
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
LifeSci Capital has reiterated its Buy rating for Aquestive Therapeutics (AQST.US) and maintained its target price at $9. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities prior to June 16, 2025, and still hold them. The investigation focuses on whether the company's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them to assist with the investigation at no cost.
Form 4 Aquestive Therapeutics Inc For: 24 June By Investing.com
This article reports on a Form 4 filing for Aquestive Therapeutics Inc. submitted on June 24th. The filing indicates insider transactions for the company (AQST). The article provides no further details beyond the existence of the filing and some financial data unrelated to the specific Form 4.
Form 4 Aquestive Therapeutics Inc For: 24 June By Investing.com
This article reports on a Form 4 filing for Aquestive Therapeutics Inc. submitted on June 24th, 2026. Form 4 filings disclose changes in beneficial ownership of company stock by insiders. The article provides the title and publication date but contains no further details about the filing itself.
Form 4 Aquestive Therapeutics Inc For: 24 June By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4 for Aquestive Therapeutics Inc. for June 24th. The content is brief, primarily serving as an announcement of the filing and indicating that more detailed information would be contained within the Form 4 document itself. The article reiterates the filing multiple times and includes market data and popular article suggestions, which are standard for financial news aggregators.
Aquestive Therapeutics director Julie Krop sells $125k in stock By Investing.com
Aquestive Therapeutics director Julie Krop sold $125,392 worth of company stock, involving 25,000 shares at $5.0157 per share, following the exercise of stock options. The sale was executed under a Rule 10b5-1 trading plan, occurring after the stock saw a 57% surge over the past year and a 13.5% gain in the last week. This transaction comes amidst strong Q1 2026 financial results for Aquestive Therapeutics and a "Market Outperform" rating from Citizens.
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) saw a 6.6% stock rally, closing at $5.03, driven by investor confidence in its lead product candidate, Anaphylm, and its development pipeline. The company plans to resubmit its NDA for Anaphylm in Q3 2026 and is also advancing AQST-108. Despite robust revenue and earnings growth expectations for the upcoming quarter, the stock's future strength is uncertain as its consensus EPS estimate has remained unchanged, and trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
Does US manufacturing give drugmakers a speed edge?
Aquestive Therapeutics' quick resolution of an FDA rejection for Anaphylm, thanks to its U.S.-based manufacturing, highlights the speed advantages of domestic operations. This article explores how proximity to facilities can significantly cut down response times and complexities compared to overseas manufacturing, despite challenges like pricing pressures and the need for specialized talent. The push for reshoring manufacturing, amplified by lessons from the COVID-19 pandemic and geopolitical factors, suggests a growing preference for domestic production to enhance quality control and supply chain resilience.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aquestive Therapeutics, Inc. (AQST). The firm encourages investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The investigation aims to restore investor capital and ensure corporate accountability, with no cost to investors unless the firm is successful.
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Aquestive Therapeutics, Inc. (AQST) regarding alleged corporate wrongdoing. The firm encourages Aquestive shareholders who purchased securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The investigation is conducted on a contingency fee basis, meaning no cost to investors unless the firm is successful.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities before June 16, 2025, and continue to hold them. The firm is looking into possible corporate wrongdoing by Aquestive's officers and directors. Shareholders are encouraged to contact the firm to assist with the investigation, which is conducted on a contingency fee basis.
Have Aquestive Therapeutics Insiders Been Selling Stock?
A recent analysis indicates that insiders at Aquestive Therapeutics (NASDAQ:AQST) have been selling stock, with CEO Daniel Barber divesting US$104k worth of shares, representing 3.8% of his holdings. This follows an earlier, larger sale of US$754k. Despite these sales, insiders still own 2.8% of the company, valued at US$15m, which is considered sufficient to suggest alignment with shareholders, but the overall selling trend prompts caution.
Have Aquestive Therapeutics Insiders Been Selling Stock?
Aquestive Therapeutics' CEO, President & Director, Daniel Barber, recently sold US$104k worth of shares, following a larger sale earlier in the year. While insiders own 2.8% of the company, suggesting some alignment, the pattern of selling without recent purchases raises caution for potential investors. The article highlights that these sales, particularly those below the current price, might indicate insiders believe the shares are fully valued.
Aquestive Therapeutics Inc (AQST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Aquestive Therapeutics Inc (AQST), detailing its financial performance with a focus on regional contributions. As of the latest update, the company's revenue is primarily from the United States, accounting for 66.46% of the total, with the remainder from outside the US. The report notes that relevant data for business segments have not yet been disclosed by the company.
Aquestive Therapeutics Inc (AQST) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Aquestive Therapeutics Inc's (AQST) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock splits. The article presents current stock performance data for AQST.
Aquestive Therapeutics CEO sells $104,010 in company stock By Investing.com
The CEO of Aquestive Therapeutics, Daniel Barber, sold 25,000 shares of company stock for a total of $104,010. Following the sale, Mr. Barber still directly holds 635,574 shares. The stock is currently considered overvalued, is not profitable in the last twelve months, but the company recently exceeded Q1 2026 earnings expectations and reaffirmed its 2026 financial guidance.
SPRY - Why the Market is Wrong About the ARS Pharma vs. Aquestive "Duopoly"
The article argues that the market is mispricing ARS Pharmaceuticals (SPRY) by viewing its competition with Aquestive Therapeutics (AQST) as a zero-sum "duopoly" in the epinephrine market. Instead, the author posits that both companies' non-needle delivery methods (neffy and Anaphylm) will disrupt the traditional auto-injector market, expanding the Total Addressable Market (TAM) rather than just splitting the existing one. A conservative valuation model suggests a 3x upside for SPRY, despite risks like PBM rebates and the upcoming 2027 commercial showdown.
Aquestive Therapeutics Inc (AQST) Earnings Forecast: Future EPS & Revenue Growth Estimates
Aquestive Therapeutics Inc (AQST) has an earnings forecast score of 8.44, ranking 36th in
Aquestive Therapeutics CEO sells $104,010 in company stock
Aquestive Therapeutics CEO Daniel Barber sold 25,000 shares of company stock worth $104,010 on June 15, 2026, at an average price of $4.1604 per share. This transaction leaves him with 635,574 shares, while InvestingPro analysis indicates the stock may be overvalued as the company is not profitable. Despite the sale, Aquestive Therapeutics recently reported better-than-expected Q1 2026 financial results with increased revenue and an upcoming NDA resubmission for Anaphylm, leading Citizens to maintain a Market Outperform rating.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ:AQST) regarding corporate wrongdoing. The firm encourages Aquestive shareholders who purchased securities prior to June 16, 2025, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis, seeking reimbursement for expenses and attorney's fees only if successful.
Aquestive Therapeutics CEO sells $104,010 in company stock
Aquestive Therapeutics' CEO, Daniel Barber, sold 25,000 shares of company stock for a total of $104,010, at prices ranging from $4.14 to $4.235 per share. Despite the sale, Barber still holds 635,574 shares. The company recently reported strong Q1 2026 financial results, exceeding revenue and EPS expectations, and reaffirmed its 2026 financial guidance.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) regarding corporate wrongdoing by its officers and directors. The law firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to learn more about participating in the investigation. The firm operates on a contingency fee basis, meaning there is no direct cost to investors unless they are successful in recovering funds.
Aquestive Therapeutics (AQST) director receives 50,500 stock options grant
Aquestive Therapeutics (AQST) director Gregory B. Brown received a grant of 50,500 stock options with an exercise price of $3.99 per share. These options will vest 100% on June 10, 2027, contingent on his continued service to the company. Following this grant, Brown directly holds 75,085 shares of Common Stock and the newly issued 50,500 stock options.
Aquestive (AQST) awards Abigail Jenkins 50,500 stock options at $3.99
Aquestive Therapeutics director Abigail L. Jenkins was granted 50,500 non-qualified stock options with an exercise price of $3.99 per share. These options will vest entirely on June 10, 2027, provided she remains continuously employed by the company. This award is a compensation grant, not a market transaction, and it represents potential future ownership for Ms. Jenkins.
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) regarding corporate wrongdoing. The firm encourages stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis and aims to restore investor capital and ensure corporate accountability.
AQST: FDA progress, global expansion, and all proposals passed with strong shareholder support
Aquestive Therapeutics (AQST) shareholders strongly supported all proposals at their 2026 AGM. The meeting highlighted progress towards FDA approval and commercial launch of Anaphylm, global regulatory advancements, and ongoing pipeline development. No new material non-public information was disclosed during the Q&A session.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (AQST) for potential corporate wrongdoing. The firm encourages investors who purchased AQST securities before June 16, 2025, and continue to hold them, to contact them to assist in the investigation. The representation is on a contingency fee basis, meaning no upfront cost to investors.
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Aquestive Therapeutics, Inc. (AQST) stockholders who purchased securities prior to June 16, 2025. The investigation focuses on possible corporate wrongdoing by Aquestive and its officers/directors. The law firm encourages affected investors to contact them for more information, noting that they operate on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) for alleged corporate wrongdoing. The firm encourages stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The investigation is conducted on a contingency fee basis, meaning no cost to investors unless successful.
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gew
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) for potential corporate wrongdoing. The firm encourages investors who purchased Aquestive securities before June 16, 2025, and continue to hold them, to contact them to assist with the investigation. This action is part of the firm's focus on restoring investor capital and ensuring corporate accountability.
Aquestive Therapeutics CEO sells $35,413 in company stock
The CEO of Aquestive Therapeutics, Daniel Barber, sold 8,257 shares of the company's common stock for a total of $35,413 on May 15, 2026. This transaction follows a 75% stock return over the past year, though the shares are down 35% year-to-date. The company recently surpassed Q1 2026 earnings expectations and analysts maintain a bullish outlook.
Aquestive Therapeutics (Nasdaq:AQST) - Stock Analysis
This article provides a detailed stock analysis of Aquestive Therapeutics (AQST), highlighting its financial performance, future growth prospects, and analyst ratings. It discusses the company's key products, including Anaphylm (epinephrine sublingual film) and Libervant (diazepam buccal film), and traces the regulatory journey and market positioning of these drugs. The analysis also covers recent news, earnings guidance, and significant corporate developments, alongside competitor information and historical stock performance.
Aquestive Therapeutics (NasdaqGM:AQST) Stock Forecast & Analyst Predictions
Aquestive Therapeutics (AQST) is forecast to grow earnings and revenue significantly, with EPS expected to increase by 41.5% annually. The company recently reaffirmed its 2026 full-year revenue guidance and is navigating regulatory challenges for its product, Anaphylm, which received a Complete Response Letter from the FDA but is expected to be resubmitted in Q3 2026. AQST is also pursuing international approvals for Anaphylm and has received orphan drug exclusivity for Libervant in pediatric patients.
Aquestive Says It’s on Track to Launch Anaphylm Studies for FDA
Aquestive Therapeutics announced it is moving forward with studies required by the FDA for its epinephrine film, Anaphylm, and plans to resubmit its application in the fall of 2026. The FDA had previously declined approval due to user errors in opening the pouch and incorrect placement of the film. Aquestive is awaiting FDA review of its study protocol and anticipates having study results by August to address these concerns, aiming for approval for use in adults and children over 66 pounds.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2026 Earnings Call Transcript
Aquestive Therapeutics (NASDAQ:AQST) discussed its Q1 2026 financial results and provided updates on its key product Anaphylm and pipeline asset AQST-108. The company reiterated its expectation for a Q3 resubmission of Anaphylm's NDA to the FDA, contingent on timely feedback, and highlighted progress in securing a new debt facility and preparing for commercial launch. Additionally, early Phase I data for AQST-108 showed promising directional signals for dermatological indications.
Aquestive Therapeutics (AQST) Q1 Loss Per Share Narrows Challenging Bearish Narratives
Aquestive Therapeutics (AQST) reported Q1 2026 revenue of US$14.4 million and a narrowed EPS loss of US$0.07, an improvement from Q1 2025's US$0.24 loss. Despite growing revenue, the company continues to incur significant losses, with trailing twelve-month net loss at US$68.9 million. The stock trades at a high P/S multiple, indicating investor confidence in future profitability, but analysts note the slow pace of loss reduction and negative shareholder equity.
Aquestive Therapeutics: Q1 Earnings Snapshot
Aquestive Therapeutics Inc. (AQST) reported a first-quarter loss of $8.1 million, or 7 cents per share, which exceeded Wall Street expectations. The company also posted revenue of $14.4 million, surpassing analyst forecasts. Shares of Aquestive Therapeutics were trading significantly higher than a year ago.
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics announced its first-quarter 2026 financial results, highlighting a 66% revenue increase to $14.4 million and a reduced net loss of $8.1 million. The company reaffirmed its plan to resubmit the Anaphylm™ sublingual film NDA in Q3 2026 and provided updates on its AQST-108 topical gel and a new $150 million debt facility. Aquestive's 2026 financial guidance remains unchanged, projecting $46 to $50 million in total revenue.
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics announced its first quarter 2026 financial results, reporting a significant increase in total revenues to $14.4 million, up 66% from the previous year. The company reaffirmed its guidance to resubmit the Anaphylm™ New Drug Application (NDA) in Q3 2026 and provided updates on its AQST-108 phase 1 study, its global regulatory strategy for Anaphylm, and a new $150 million debt facility with Oaktree Capital Management, L.P. The net loss for the quarter substantially decreased to $8.1 million from $22.9 million in Q1 2025.
Aquestive Therapeutics Inc - enters five-year term loan facility of up to $150 million on May 12, 2026 - SEC filing
Aquestive Therapeutics Inc. has announced that it entered into a five-year term loan facility for up to $150 million on May 12, 2026. This information was disclosed in an SEC filing. The article provides this key financial update along with other recent company news and financial data.
Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Inc. has entered into a five-year term loan facility for up to $150 million. This financial arrangement was made on May 12, 2026, and was disclosed in an SEC filing.
12 Health Care Stocks Moving In Wednesday's After-Market Session - Aquestive Therapeutics (NASDAQ:AQST)
This article details 12 health care stocks that experienced significant movement in Wednesday's after-market session. Several companies, including Staar Surgical, Precision Optics Corp, and Aquestive Therapeutics, saw their shares rise following recent earnings reports. Conversely, MDxHealth, Doximity, and DarioHealth were among those whose stocks declined in the same period.
BRIEF-Aquestive Therapeutics, Inc. Q1 Revenue USD 14.446 Million Vs. IBES Estimate USD 10.9 Million
Aquestive Therapeutics, Inc. reported its Q1 revenue at USD 14.446 million, significantly surpassing the IBES estimate of USD 10.9 million. This brief financial update indicates stronger-than-expected performance for the company in the first quarter.
